Ovarian Cancer Treatment Found to Significantly Improve Survival

	Tweet

According to a study published in the January 5 issue of the New England Journal of Medicine, women with Stage III ovarian cancer given a combination of intravenous (IV) and intra-abdominal chemotherapy, following the successful surgical removal of tumors, experienced a median survival time 16 months longer than women who received IV chemotherapy alone.

Intra-abdominal chemotherapy, also known as intraperitoneal (IP) chemotherapy, involves the delivery of anticancer drugs directly into the abdomen. This type of chemotherapy administration is underutilized, but significant evidence from this new study confirms the survival benefit of IP chemotherapy for most women with advanced ovarian cancer.

The study, conducted by Deborah K. Armstrong, MD, an assistant professor at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland, and her colleagues, builds upon evidence from eight other clinical trials - including those conducted at Memorial Sloan-Kettering Cancer Center (MSKCC) - showing an overall survival period of approximately one year for women treated with IP chemotherapy after “optimal debulking” - surgery to remove most, if not all, of the cancer in the abdomen.

Based on this overwhelming evidence, the National Cancer Institute (NCI) will issue a clinical announcement on January 5 encouraging the administration of a combination of IV and IP chemotherapy to treat women with advanced ovarian cancer, who have undergone optimal surgical debulking.

After pioneering the first clinical trials of IP chemotherapy in the late 1980s, MSKCC is one of the most experienced centers with the largest volume of patients who have undergone the procedure. The Center has been using IP chemotherapy as a standard of care based on Dr. Armstrong’s presentation at the American Society of Clinical Oncology’s annual meeting in May 2005 and research conducted at MSKCC.

Patients who have undergone the procedure and gynecological oncologists experienced in performing it are available for interview.

RELATED STORIES:
Ovarian cancer screening popular despite guidelines   Ovarian cancer risk not affected by alcohol and smoking, but reduced by caffeine   UBC discovery may lead to ‘smart’ therapies for breast, ovarian cancer   Symptom screening plus a simple blood test improves early detection of ovarian cancer   Ovarian Cancer May Mimic Fallopian Tube Formation   Screening misses early ovarian cancer   Study unmasks how ovarian tumors evade immune system   Proteins show promise for ovarian cancer screening   Optimistic women with ovarian cancer fare better   Ginkgo may ward off ovarian cancer   Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers   Motor protein may offer promise in ovarian cancer treatment   Soy may lessen risk of endometrial, ovarian cancers   Body cavity drugs cut ovarian cancer death risk   Trial of Topotecan following Carboplatin and Paclitaxel in treatment of ovarian cancer   Stem Cells Could be Used for Personalized Cancer Treatment   New technique could sustain cancer patients’ fertility   Ovary removal could be risky for young women   Genetic factors implicated in survival gap for breast, ovarian or prostate cancer   Short-term OC use cuts ovarian cancer risk   Obesity may raise risk of ovarian cancer   Two gene mutations mark deadly ovarian cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]